FAROSON US LLC – Trademark Portfolio

Entity Type: 16

FAROSON US LLC holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include NUCOS and FAROSON. The owner is based in GARDEN GROVE, CA.

12913 HARBOR BLVD, STE Q - 3 #286

GARDEN GROVE, CA 92840

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NUCOS
NUCOS
Registered 2019
FAROSON
FAROSON
Registered 2018

Trademark Classifications

FAROSON US LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does FAROSON US LLC have?

FAROSON US LLC has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does FAROSON US LLC file in?

FAROSON US LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are FAROSON US LLC's most well-known trademarks?

FAROSON US LLC's registered trademark portfolio includes well-known marks such as NUCOS and FAROSON. These are among 2 currently registered trademarks in the portfolio.

What is FAROSON US LLC's trademark registration success rate?

FAROSON US LLC has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.